Management ChangeOct 8, 2026, 04:16 PM
Aardvark Therapeutics Appoints David Zhang to Board of Directors
AI Summary
Aardvark Therapeutics, Inc. announced the appointment of David (Zhongwei) Zhang, Ph.D., MBA, to its Board of Directors, effective October 7, 2026. Dr. Zhang brings extensive experience in clinical development, regulatory affairs, and biostatistics from his previous roles at prominent biotechnology companies. As a non-employee director, he will receive $40,000 in annual cash compensation and a stock option award valued at $500,000. The company also entered into a standard indemnification agreement with Dr. Zhang.
Key Highlights
- Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director.
- Dr. Zhang brings over 25 years of experience in clinical strategy, biostatistics, and regulatory submissions.
- He previously held leadership roles at Abivax S.A., Alumis Inc., and MyoKardia, Inc.
- Dr. Zhang will receive $40,000 annually in cash compensation as a non-employee director.
- He was granted an option to purchase Aardvark common stock valued at $500,000, vesting over 36 months.
Price Impact
More from AARD